Our mission is to deliver solutions and bring hope to as many people as possible.
Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.
More info
FDA PLAN TO ENCOURAGE BIOSIMILAR MEDICINAL PRODUCTS IN THE UNITED STATES
In 1984, the United States approved the Hatch Waxman Act to boost competition among generic medicinal products. These now comprise 90% of prescriptions across the country, generating [...]
+
mAbxience, sponsor of BIOSPAIN 2018
BIOSPAIN, the largest biotech event organized by a national bioindustry association in Europe (ASEBIO), and one of the largest in the world by the number of one-to-one [...]
+
Our business model is B2B (business to business), which allows us to market our products worldwide through our consolidated network of local partners, all leaders in their markets.
+